

Mitchell Machtay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2597151/publications.pdf>

Version: 2024-02-01

81
papers

1,774
citations

394421

19
h-index

276875

41
g-index

81
all docs

81
docs citations

81
times ranked

2928
citing authors

#	ARTICLE	IF	CITATIONS
1	A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3241.	2.6	1
2	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores – A pooled analysis of RTOG 0129 and 0522. <i>Oral Oncology</i> , 2021, 116, 105241.	1.5	6
3	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. <i>Future Oncology</i> , 2021, 17, 2713-2724.	2.4	2
4	Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. <i>Radiotherapy and Oncology</i> , 2021, 162, 26-33.	0.6	10
5	Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning. <i>Frontiers in Oncology</i> , 2021, 11, 744130.	2.8	2
6	Stereotactic body radiotherapy (SBRT) for T2N0 (> 3 cm) non-small cell lung cancer: Outcomes and failure patterns. <i>Journal of Radiosurgery and SBRT</i> , 2021, 7, 271-277.	0.2	0
7	A framework for modeling radiation induced lymphopenia in radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 144, 105-113.	0.6	26
8	Clinical Study of Using Biometrics to Identify Patient and Procedure. <i>Frontiers in Oncology</i> , 2020, 10, 586232.	2.8	2
9	Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 483-485.	0.8	4
10	Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 587-596.	0.8	8
11	Delayed response to proton beam treatment of hepatocellular carcinoma. <i>BJR case Reports</i> , 2020, 6, 20180125.	0.2	1
12	Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review. <i>Neuro-Oncology Practice</i> , 2020, 7, 541-548.	1.6	5
13	Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?. <i>Radiotherapy and Oncology</i> , 2020, 149, 55-62.	0.6	84
14	Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation. <i>Translational Lung Cancer Research</i> , 2020, 9, 2315-2327.	2.8	8
15	Changes of plasma GARP-LTGF β 1 complex during chemoradiotherapy may predict survival in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21042-e21042.	1.6	0
16	Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9027-9027.	1.6	0
17	NCOG-33. HEMATOLOGIC PREDICTORS OF OUTCOMES IN GLIOBLASTOMA TREATED WITH SURGERY AND CHEMORADIATION. <i>Neuro-Oncology</i> , 2020, 22, ii136-ii136.	1.2	0
18	Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus Paper. <i>Practical Radiation Oncology</i> , 2019, 9, 395-401.	2.1	20

#	ARTICLE	IF	CITATIONS
19	Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 794-800.	6.4	11
20	Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [18F]FDG PET/CT. <i>Oral Oncology</i> , 2019, 93, 101-106.	1.5	4
21	Evaluating radiotherapy treatment delay using Failure Mode and Effects Analysis (FMEA). <i>Radiotherapy and Oncology</i> , 2019, 137, 102-109.	0.6	12
22	Comparison of multiparametric MRI-based and transrectal ultrasound-based preplans with intraoperative ultrasound-based planning for low dose rate interstitial prostate seed implantation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 31-38.	1.9	6
23	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e129-e133.	2.1	1
24	Assessment of beam-matched linacs quality/accuracy for interchanging SBRT or SRT patient using VMAT without replanning. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 68-75.	1.9	19
25	Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6073-6073.	1.6	19
26	An Integrated Framework Based on Full Monte Carlo Simulations for Double-Scattering Proton Therapy. <i>International Journal of Particle Therapy</i> , 2019, 6, 31-41.	1.8	0
27	Reirradiation for Recurrent Scalp Angiosarcoma: Dosimetric Advantage of PBT over VMAT and EBT. <i>International Journal of Particle Therapy</i> , 2019, 6, 13-18.	1.8	2
28	Technical Note: An approach to building a Monte Carlo simulation model for a double scattering proton beam system. <i>Medical Physics</i> , 2018, 45, 2660-2666.	3.0	2
29	Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 125-130.	1.9	6
30	3T multiparametric MRI-guided high-dose-rate combined intracavitary and interstitial adaptive brachytherapy for the treatment of cervical cancer with a novel split-ring applicator. <i>Brachytherapy</i> , 2018, 17, 334-344.	0.5	7
31	Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 606-617.	0.8	68
32	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 595-605.	0.8	101
33	Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 586-594.	0.8	105
34	NCMP-01. COMPARISON AND QUANTITATION OF HISTOPATHOLOGY ABNORMALITIES IN SURGICALLY RESECTED CEREBRAL RADIATION NECROSIS AS COMPARED WITH RECURRENT BRAIN TUMOR FOLLOWING RADIATION. <i>Neuro-Oncology</i> , 2018, 20, vi194-vi194.	1.2	0
35	Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6010-6010.	1.6	28
36	Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8539-8539.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Phase I/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent glioblastoma (rGBM).. Journal of Clinical Oncology, 2018, 36, TPS2074-TPS2074.	1.6	3
38	Post-treatment PET/CT and p16 status for predicting treatment outcomes in locally advanced head and neck cancer after definitive radiation. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 988-997.	6.4	15
39	A Monte Carlo model and its commissioning for the Leksell Gamma Knife Perfexion radiosurgery system. Medical Physics, 2017, 44, 4910-4918.	3.0	4
40	Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy. Head and Neck, 2017, 39, 527-532.	2.0	23
41	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. Future Oncology, 2017, 13, 1405-1414.	2.4	19
42	Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review. Future Oncology, 2017, 13, 649-663.	2.4	19
43	Development and Validation of a Small Animal Immobilizer and Positioning System for the Study of Delivery of Intracranial and Extracranial Radiotherapy Using the Gamma Knife System. Technology in Cancer Research and Treatment, 2017, 16, 203-210.	1.9	4
44	Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer. Translational Lung Cancer Research, 2017, 6, 713-715.	2.8	3
45	Results of stereotactic body radiation therapy (SBRT) for T2 lung cancer: Outcomes of longer term follow-up.. Journal of Clinical Oncology, 2017, 35, 8542-8542.	1.6	1
46	A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- liriumab (Liri) or ipilimumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).. Journal of Clinical Oncology, 2017, 35, TPS6097-TPS6097.	1.6	4
47	Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E1770-6.	2.0	12
48	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age > 65 years) using national SEER-Medicare data. Practical Radiation Oncology, 2016, 6, e163-e169.	2.1	12
49	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. Expert Review of Anticancer Therapy, 2016, 16, 1131-1144.	2.4	0
50	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. Radiotherapy and Oncology, 2016, 121, 335-341.	0.6	14
51	Comparison of Ray Tracing and Monte Carlo Calculation Algorithms for Thoracic Spine Lesions Treated With CyberKnife-Based Stereotactic Body Radiation Therapy. Technology in Cancer Research and Treatment, 2016, 15, 196-202.	1.9	18
52	Pretreatment ¹⁸ F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. Journal of Nuclear Medicine, 2016, 57, 842-848.	5.0	75
53	Experimental Validation of Monte Carlo Simulations Based on a Virtual Source Model for TomoTherapy in a RANDO Phantom. Technology in Cancer Research and Treatment, 2016, 15, 796-804.	1.9	0
54	Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers, 2015, 7, 981-1004.	3.7	81

#	ARTICLE	IF	CITATIONS
55	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 156-164.	1.6	216
56	Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2015, 37, 1665-1671.	2.0	43
57	Quantitative evaluation of image segmentation incorporating medical consideration functions. <i>Medical Physics</i> , 2015, 42, 3013-3023.	3.0	24
58	Pretreatment FDG-PET Metrics in Stage III Non-Small Cell Lung Cancer: ACRIN 6668/RTOG 0235. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv004-djv004.	6.3	59
59	Quantitative Analysis Tools and Digital Phantoms for Deformable Image Registration Quality Assurance. <i>Technology in Cancer Research and Treatment</i> , 2015, 14, 428-439.	1.9	10
60	Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the riskâ€“benefit ratio. <i>Future Oncology</i> , 2015, 11, 2405-2415.	2.4	20
61	Regional Lymph Node Uptake of [18F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 597-605.	0.8	19
62	Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015, 117, 183-187.	0.6	93
63	Application of positron emission tomography/computed tomography in radiation treatment planning for head and neck cancers. <i>World Journal of Radiology</i> , 2015, 7, 382.	1.1	6
64	Cardiovascular risk profile and management in patients with head and neck cancer treated with radiotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17081-e17081.	1.6	0
65	Establishing a process of irradiating small animal brain using a CyberKnife and a microCT scanner. <i>Medical Physics</i> , 2014, 41, 021715.	3.0	11
66	Stereotactic radiosurgery for more than four brain metastases. <i>Lancet Oncology</i> , The, 2014, 15, 362-363.	10.7	3
67	Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. <i>Journal of Clinical Oncology</i> , 2014, 32, 2486-2495.	1.6	180
68	RTOG 9003: Legacies of a Landmark Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 253-254.	0.8	3
69	Acceler-Dated Fractionation: The End of the Era of the Large, â€œOne Size Fits Allâ€“Trial for Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 7-9.	0.8	1
70	Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6070-6070.	1.6	3
71	Comparison of cisplatin- versus carboplatin-based concurrent chemoradiation for limited-stage small cell lung cancer using SEER-Medicare data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7596-7596.	1.6	1
72	Prediction of Survival by [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3823-3830.	1.6	162

#	ARTICLE	IF	CITATIONS
73	Multicentre results of stereotactic body radiotherapy for secondary liver tumours. <i>Hpb</i> , 2013, 15, 851-857.	0.3	28
74	Stereotactic body radiation therapy for metastasis in the lung: an undervalued treatment option with future prospects. <i>Lung Cancer Management</i> , 2012, 1, 73-79.	1.5	1
75	Radiation Treatment Planning for Head and Neck Cancer with PET. <i>PET Clinics</i> , 2012, 7, 395-410.	3.0	1
76	Imaging follow-up after stereotactic ablative radiotherapy (SABR) for lung tumors. <i>Journal of Radiation Oncology</i> , 2012, 1, 11-16.	0.7	5
77	Composite radiation dose representation using Fuzzy Set theory. <i>Information Sciences</i> , 2012, 187, 204-215.	6.9	7
78	The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): An analysis of RTOG 0129.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5530-5530.	1.6	0
79	O6-benzylguanine (BG) and temozolomide (TMZ) therapy of glioblastoma multiforme (GBM) with infusion of autologous lentiviral transduced P140KMGMT+ hematopoietic progenitors to protect hematopoiesis: A phase I study.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1616-TPS1616.	1.6	0
80	The Role of PET in the Evaluation, Treatment, and Ongoing Management of Lung Cancer. <i>PET Clinics</i> , 2011, 6, 265-274.	3.0	0
81	The Role of PET in the Evaluation, Treatment, and Ongoing Management of Lung Cancer. <i>PET Clinics</i> , 2011, 6, 177-184.	3.0	0